摘要
目的:观察卡维地洛对扩张型心肌病(DCM)患者血清心肌肌钙蛋白Ⅰ(cTnⅠ)和超敏C反应蛋白(hs-CRP)的影响。方法:34例DCM患者(DCM组)在常规治疗(包括硝酸酯类、洋地黄、利尿剂等)基础上给予卡维地洛治疗,连续6个月,观察治疗前后心率(HR)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)改善情况;检测血清cTnⅠ、hs-CRP水平,并与同期30名健康体检者(正常组)对照。结果:卡维地洛治疗后DCM患者HR、LVESD、LVEDD、LVEF均显著改善,与治疗前比较,差异有统计学意义(P<0.01),DCM总有效率为91.2%;治疗前DCM患者血清cTnⅠ、hs-CRP水平均显著升高,与正常组比较,差异有统计学意义(P<0.05);卡维地洛治疗后患者血清cTnⅠ、hs-CRP水平显著降低(P<0.01),但仍高于正常组(P<0.05)。结论:卡维地洛能降低DCM患者血清cTnⅠ、hs-CRP水平,显著改善心功能和血流动力学,改善心室重构,且耐受性较好。
OBJECTIVE： To observe the effects of carvedilol on dilated cardiomyopathy （DCM） in serum of patients with car- diac troponin I （cTn I ） and high sensitive C reactive protein （hs-CRP） effect. METHODS： 34 cases of DCM patients in the con- ventional treatment （including nitrates, digitalis, diuretics） based on the given carvedilol therapy, for 6 consecutive months, ob- served before the treatment, heart rate （HR）, left ventricular end systolic diameter （LVESD）, left ventricular end diastolic diame- ter （LVEDD）, left ventricular ejection fraction （LVEF） to improve the situation; the detection of serum cTn I , hs-CR_P levels, and with the same period in 30 healthy persons in the control. RESULTS： After carvedilol treatment in patients with DCM HR, LVESD, LVEDD, LVEF were significantly improved, compared with before treatment, the difference was statistically significant （P〈0.01）, the total efficiency of DCM was 91.2%; DCM in serum of patients with cTn I , hs-CRP were significantly higher, compared with the normal group, the difference was statistically serum cTn I , hs-CRP were significantly reduced （P〈0.01）but Carvedilol can reduce DCM patients with serum cTn I , hs-CRP namics, improve ventricular remodeling, and well tolerated. significant （P〈0.05） ; after carvedilol treatment in patients with still higher than the normal group （P〈0.05）. CONCLUSIONS： levels, significant improvement of cardiac function and hemody-
出处
《中国药房》
CAS
CSCD
2013年第8期705-707,共3页
China Pharmacy
